Obesity also inhibits the efficacy of anti-VEGF targeted therapy by enhancing the activity of FGF-2 pathway in breast cancer (Incio et al., 2018). The gene discussed is FGF2; the disease is obesity due to melanocortin 4 receptor deficiency.